Clover Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Clover Biopharmaceuticals has a total shareholder equity of CN¥-1.6B and total debt of CN¥74.0M, which brings its debt-to-equity ratio to -4.5%. Its total assets and total liabilities are CN¥812.7M and CN¥2.4B respectively.
Key information
-4.5%
Debt to equity ratio
CN¥73.97m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥416.02m |
| Equity | -CN¥1.64b |
| Total liabilities | CN¥2.45b |
| Total assets | CN¥812.74m |
Recent financial health updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05Financial Position Analysis
Short Term Liabilities: 2197 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 2197 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 2197 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 2197's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2197 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2197 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 06:12 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clover Biopharmaceuticals, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Credit Suisse |
| Yang Huang | Credit Suisse |
| Ziyi Chen | Goldman Sachs |